• Biology, Medicine
  • Published in Folia neuropathologica 2005

CCL2 (MCP-1) and CCL5 (RANTES) levels in the peripheral blood of multiple sclerosis patients treated with Glatiramer Acetate (Copaxone).

@article{Losy2005CCL2A,
  title={CCL2 (MCP-1) and CCL5 (RANTES) levels in the peripheral blood of multiple sclerosis patients treated with Glatiramer Acetate (Copaxone).},
  author={Jacek Losy and Grażyna Michałowska-Wender and Aleksandra Kurdyńska and Mieczysław Wender},
  journal={Folia neuropathologica},
  year={2005},
  volume={43 3},
  pages={
          153-5
        }
}
The MCP-1 and RANTES levels were measured in 20 multiple sclerosis patients before and after 1 year daily treatment with 20 mg of subcutaneously applied glatiramer acetate. The level of MCP-1 in serum from multiple sclerosis patients was lower than in control subjects. After one year of therapy with glatiramer acetate, the level of MCP-1 was almost identical with that at the starting point. The concentration of RANTES in MS, both before and after therapy, did not differ from the control… CONTINUE READING

Tables and Topics from this paper.

Citations

Publications citing this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 11 REFERENCES

Interleukin 12 and interleukin 10 are affected differentially by treatment of multiple sclerosis with glatiramer acetate (Copaxone)

J Losy, G Micha3owska-Wender, M. Wender
  • Folia Neuropathol
  • 2002
VIEW 1 EXCERPT

Analysis of interleukin 18 during therapy with glatiramer acetate (Copaxone) in patients with relapsing-remitting multiple sclerosis

J Losy, G Micha3owska-Wender, M. Wender
  • Folia Neuropathol
  • 2001
VIEW 1 EXCERPT

Immunologic basic of MS

S. Khoury
  • Cokk S (ed.). Handbook of multiple sclerosis
  • 1990